The DOI matches its Crossref record; 65 of the 68 references it cites were found in a registry or an index.
Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
Open accessAbstract
In 2012, the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) published a position statement on the management of hyperglycemia in patients with type 2 diabetes (1,2). This was needed because of an increasing array of antihyperglycemic drugs and growing uncertainty regarding their proper selection and sequence. Because of a paucity of comparative effectiveness research on long-term treatment outcomes with many of these medications, the 2012 publication was less prescriptive than prior consensus reports. We previously described the need to individualize both treatment targets and treatment strategies, with an emphasis on patient-centered care and shared decision making, and this continues to be our position, although there are now more head-to-head trials that show slight variance between agents with regard to glucose-lowering effects. Nevertheless, these differences are often small and would be unlikely to reflect any definite differential effect in an individual patient. The ADA and EASD have requested an update to the position statement incorporating new data from recent clinical trials. Between June and September of 2014, the Writing Group reconvened, including one face-to-face meeting, to discuss the changes. An entirely new statement was felt to be unnecessary. Instead, the group focused on those areas where revisions were suggested by a changing evidence base. This briefer article should therefore be read as an addendum to the previous full account (1,2). Glucose control remains a major focus in the management of patients with type 2 diabetes. However, this should always be in the context of a comprehensive cardiovascular risk factor reduction program, to include smoking cessation and the adoption of other healthy lifestyle habits, blood pressure control, lipid management with priority to statin medications, and, in some circumstances, antiplatelet therapy. Studies have conclusively determined that reducing hyperglycemia decreases the onset and progression of …
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Strong evidence supports the ef fi cacy and cost-effectiveness of nutrition therapy as a component of quality diabetes care, including its integration into the medical management of diabetes”
From Nutrition Therapy for Adults With Diabetes or Prediabetes: A Consensus Report (2019) · cites this paper as [2]
Citations
Cites
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Self-citationDormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
Self-citationSaxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetes Care · doi:10.2337/dc12-0413 · Cited by 3,207
Self-citationAlogliptin after acute coronary syndrome in patients with type 2 diabetes
White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305889 · Cited by 2,502
Self-citation
Cited by
Sorted by citations
Items 301–400 of 1,014
Min, S. H., Yoon, J., Hahn, S., & Cho, Y. M. (2016) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2818 · Cited by 87
Shah, P., Chavda, K., Vyas, B., & Patel, S. (2020) · Drug Delivery and Translational Research · doi:10.1007/s13346-020-00839-9 · Cited by 86
Hansen, M., Sonne, D. P., Mikkelsen, S. U., Gluud, L. L., Vilsbøll, T., & Knop, F. K. (2017) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2017.01.011 · Cited by 86
Ten years of experience with DPP-4 inhibitors for the treatment of type 2 diabetes mellitus
Sesti, G., Avogaro, A., Belcastro, S., Bonora, B. M., Croci, M., Daniele, G., Dauriz, M., Dotta, F., Formichi, C., Frontoni, S., et al. (2019) · Acta Diabetologica · doi:10.1007/s00592-018-1271-3 · Cited by 86
Townsend, R. R., Machin, I., Ren, J., Trujillo, A., Kawaguchi, M., Vijapurkar, U., Damaraju, C. V., & Pfeifer, M. (2016) · The Journal of Clinical Hypertension · doi:10.1111/jch.12747 · Cited by 85
Xiao, D., Yu, G., Li, X., Yin, J., Zheng, W., Qiu, X., Xiao, L., Liu, R., Wang, S., Gong, W., et al. (2016) · International Journal of Endocrinology · doi:10.1155/2016/4350712 · Cited by 85
The role of KATP channels in cerebral ischemic stroke and diabetes
Szeto, V., Chen, N., Sun, H., & Feng, Z. (2018) · Acta Pharmacologica Sinica · doi:10.1038/aps.2018.10 · Cited by 85
DMTO: a realistic ontology for standard diabetes mellitus treatment
El–Sappagh, S., Kwak, D., Ali, F., & Kwak, K.-S. (2018) · Journal of Biomedical Semantics · doi:10.1186/s13326-018-0176-y · Cited by 85
Chan, S. P., & Colagiuri, S. (2015) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.07.002 · Cited by 84
Insulin Initiation and Titration in Patients With Type 2 Diabetes
Chun, J. H., Strong, J. L., & Urquhart, S. (2018) · Diabetes Spectrum · doi:10.2337/ds18-0005 · Cited by 84
The past, present, and future of basal insulins
Pettus, J., Cavaiola, T. S., Tamborlane, W. V., & Edelman, S. V. (2015) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2763 · Cited by 83
Liatis, S., Dafoulas, G., Kani, C., Politi, A., Litsa, P., Sfikakis, P. P., & Makrilakis, K. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2016.06.018 · Cited by 83
Abdulrhim, S. H., Sankaralingam, S., Ibrahim, M. I. M., & Awaisu, A. (2020) · Primary care diabetes · doi:10.1016/j.pcd.2019.12.007 · Cited by 83
Ritu, M., & Johri, N. (2016) · Journal of the Science of Food and Agriculture · doi:10.1002/jsfa.7627 · Cited by 83
Trends of antidiabetic drug use in adult type 2 diabetes in Korea in 2002–2013
Ko, S., Kim, D. J., Park, J. H., Park, C., Jung, C. H., Kwon, H., Park, J., Song, K., Han, K., Lee, K.-U., et al. (2016) · Medicine · doi:10.1097/md.0000000000004018 · Cited by 84
Lind, M., Hirsch, I. B., Tuomilehto, J., Dahlqvist, S., Ahrén, B., Torffvit, O., Attvall, S., Ekelund, M., Filipsson, K., Tengmark, B.-O., et al. (2015) · BMJ · doi:10.1136/bmj.h5364 · Cited by 82
Metformin upregulates mitophagy in patients with T2DM: A randomized placebo‐controlled study
Bhansali, S., Bhansali, A. K., Dutta, P. R., Walia, R., & Dhawan, V. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14834 · Cited by 82
Baxter, S. M., Lund, L. C., Andersen, J. H., Brix, T. H., Hegedüs, L., Hsieh, M. H.-C., Su, C. T.-T., Cheng, M. C.-Y., Chang, Z. C.-J., Lai, E. C.-C., et al. (2025) · Thyroid® · doi:10.1089/thy.2024.0387 · Cited by 81
Nyström, T., Bodegård, J., Nathanson, D., Thuresson, M., Norhammar, A., & Eriksson, J. W. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12889 · Cited by 81
Burton, J. H., Johnson, M., Johnson, J. L., Hsia, D. S., Greenway, F. L., & Heiman, M. L. (2015) · Journal of Diabetes Science and Technology · doi:10.1177/1932296815577425 · Cited by 81
SGLT2 inhibitors in the management of type 2 diabetes
Reddy, R. P. M., & Inzucchi, S. E. (2016) · Endocrine · doi:10.1007/s12020-016-0943-4 · Cited by 80
Self-citationZhang, K., Yang, W., Dai, H., & Deng, Z. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108001 · Cited by 80
Exploring the Pharmacological Potential of Metformin for Neurodegenerative Diseases
Du, M., Gao, Q.-Y., Liu, C., Bai, L.-Y., Li, T. X., & Wei, F. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.838173 · Cited by 80
Siavash, M., Tabbakhian, M., Sabzghabaee, A. M., & Razavi, N. (2017) · Journal of Research in Pharmacy Practice · doi:10.4103/jrpp.jrpp_17_2 · Cited by 80
Li, T., Yang, C., Tseng, S.-T., Li, C.-I., Liu, C.-S., Lin, W., Hwang, K.-L., Yang, S.-Y., Chiang, J., & Lin, C. (2017) · Diabetes Care · doi:10.2337/dc16-2238 · Cited by 80
Guja, C., Frías, J. P., Somogyi, A., Jabbour, S. A., Wang, H., Hardy, E., & Rosenstock, J. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13266 · Cited by 80
Ajjan, R. A., Jackson, N., & Thomson, S. A. (2019) · Diabetes and Vascular Disease Research · doi:10.1177/1479164119827456 · Cited by 79
“Those related to sensor insertion were bleeding (5), bruising (4), pain (2), oedema (1) and induration (0).”
BackgroundThe right place for metformin today
Schernthaner, G., & Schernthaner, G.-H. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.107946 · Cited by 81
Metformin and Breast Cancer: Molecular Targets
Faria, J., Negalha, G. D. C., Azevedo, A., & Martel, F. (2019) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-019-09429-z · Cited by 79
Davies, M. J., Chatterjee, S., & Khunti, K. (2016) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s82008 · Cited by 78
Okur, M. E., Karantas, I. D., & Siafaka, P. I. (2017) · ACTA Pharmaceutica Sciencia · doi:10.23893/1307-2080.aps.0555 · Cited by 78
Diabetes duration and glycaemic control as predictors of cardiovascular disease and mortality
Li, F., Yang, H., Zhou, R., Zheng, J., Chen, G., Zou, M., Wu, X., & Wu, X. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14348 · Cited by 78
Svensson, E., Baggesen, L. M., Johnsen, S. P., Pedersen, L., Nørrelund, H., Buhl, E. S., Haase, C. L., & Thomsen, R. W. (2017) · Diabetes Care · doi:10.2337/dc16-2271 · Cited by 77
Romera, I., Cebrián-Cuenca, A., Álvarez-Guisasola, F., Gomez-Peralta, F., & Reviriego, J. (2019) · Diabetes Therapy · doi:10.1007/s13300-018-0535-9 · Cited by 77
Mirea, A.-M., Toonen, E. J. M., van den Munckhof, I., Munsterman, I. D., Tjwa, E. T. T. L., Jaeger, M., Oosting, M., Schraa, K., Rutten, J. H. W., van der Graaf, M., et al. (2019) · Molecular Medicine · doi:10.1186/s10020-019-0084-3 · Cited by 77
Cancer Biology and Prevention in Diabetes
Srivastava, S. P., & Goodwin, J. E. (2020) · Cells · doi:10.3390/cells9061380 · Cited by 77
Tang, H., Cui, W., Li, D., Wang, T., Zhang, J., Zhai, S., & Song, Y. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12785 · Cited by 77
Standl, E., Stevens, S. R., Armstrong, P. W., Buse, J. B., Chan, J. C. N., Green, J. B., Lachin, J. M., Scheen, A., Travert, F., Van de Werf, F., et al. (2018) · Diabetes Care · doi:10.2337/dc17-1778 · Cited by 76
Self-citationCurtis, H. J., Dennis, J., Shields, B. M., Walker, A. J., Bacon, S., Hattersley, A. T., Jones, A. G., & Goldacre, B. M. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13346 · Cited by 76
Ritzel, R. A., Roussel, R., Giaccari, A., Vora, J. P., Brulle-Wohlhueter, C., & Yki‐Järvinen, H. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13105 · Cited by 75
Benedetti, R., Benincasa, G., Glass, K., Chianese, U., Vietri, M. T., Congi, R., Altucci, L., & Claudio Napoli, A. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.106039 · Cited by 75
Wilkins, C. A., Hamman, H., Hamman, J. H., & Steenekamp, J. H. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16020178 · Cited by 75
Lucidi, P., Porcellati, F., Andreoli, A. M., Carriero, I., Candeloro, P., Cioli, P., Bolli, G. B., & Fanelli, C. G. (2015) · Diabetes Care · doi:10.2337/dc15-0801 · Cited by 75
Blonde, L., Stenlöf, K., Fung, A., Xie, J., Canovatchel, W. J., & Meininger, G. E. (2016) · Postgraduate Medicine · doi:10.1080/00325481.2016.1169894 · Cited by 74
Zhang, L., Chen, Q., Li, L., Kwong, J. S. W., Jia, P., Zhao, P., Wang, W., Zhou, X., Zhang, M., & Sun, X. (2016) · Scientific Reports · doi:10.1038/srep32649 · Cited by 74
Effect of anti-diabetic drugs on bone metabolism: Evidence from preclinical and clinical studies
Adil, M., Khan, R. A., Kalam, A., Venkata, S. K., Kandhare, A. D., Ghosh, P., & Sharma, M. (2017) · Pharmacological Reports · doi:10.1016/j.pharep.2017.05.008 · Cited by 74
Arnold, S. V., Kosiborod, M., Wang, J., Fenici, P., Gannedahl, G., & LoCasale, R. J. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13303 · Cited by 74
Rosenstock, J., Nino, A., Soffer, J., Erskine, L., Acusta, A., Dole, J., Carr, M. C., Mallory, J., & Home, P. (2020) · Diabetes Care · doi:10.2337/dc19-2316 · Cited by 73
Current perspectives on cardiovascular outcome trials in diabetes
on behalf of the D&CVD EASD Study Group, Schnell, O., Rydén, L., Standl, E., & Ceriello, A. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0456-8 · Cited by 73
Warren, M., CHAYKIN, L. B., Trachtenbarg, D. E., Nayak, G., Wijayasinghe, N., & Cariou, B. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13331 · Cited by 73
The “A to Z” of Managing Type 2 Diabetes in Culturally Diverse Populations
Caballero, A. E. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00479 · Cited by 73
Sex Differences in Adverse Drug Reactions of Metformin: A Longitudinal Survey Study
de Vries, S. T., Denig, P., Ekhart, C., Mol, P. G. M., & van Puijenbroek, E. (2020) · Drug Safety · doi:10.1007/s40264-020-00913-8 · Cited by 73
Tighe, S. A., Ball, K., Kensing, F., Kayser, L., Rawstorn, J. C., & Maddison, R. (2020) · Journal of Medical Internet Research · doi:10.2196/16774 · Cited by 73
Racial/ethnic disparities in prevalence and care of patients with type 2 diabetes mellitus
Ferdinand, K. C., & Nasser, S. A. (2015) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1029894 · Cited by 73
Wu, J. W., Filion, K. B., Azoulay, L., Doll, M. K., & Suissa, S. (2016) · Diabetes Care · doi:10.2337/dc15-1816 · Cited by 73
Leonard, C. E., Han, X., Brensinger, C. M., Bilker, W. B., Cardillo, S., Flory, J., & Hennessy, S. (2017) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.4337 · Cited by 73
Mata‐Cases, M., Franch‐Nadal, J., Real, J., Gratacòs, M., López‐Simarro, F., Khunti, K., & Mauricio, D. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13045 · Cited by 72
Inagaki, N., Harashima, S., Maruyama, N., Kawaguchi, Y., Goda, M., & Iijima, H. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0407-4 · Cited by 72
Huang, Y., Shiyanbola, O. O., & Chan, H. (2018) · Patient Education and Counseling · doi:10.1016/j.pec.2018.06.010 · Cited by 72
The current role of thiazolidinediones in diabetes management
Rizos, C. V., Kei, A. A., & Elisaf, M. (2016) · Archives of Toxicology · doi:10.1007/s00204-016-1737-4 · Cited by 71
2023 Guidelines on the management of patients with diabetes - a position of Diabetes Poland
Araszkiewicz, A., Bandurska-Stankiewicz, E. M., Borys, S., Budzynski, A. Z., Cyganek, K., Cypryk, K., Czech, A., Czupryniak, L., Drzewoski, J., Dzida, G. J., et al. (2023) · Current Topics in Diabetes · doi:10.5114/ctd/160061 · Cited by 72
Gallo, M., Muscogiuri, G., Felicetti, F., Faggiano, A., Trimarchi, F., Arvat, E., Vigneri, R., & Colao, A. (2017) · Metabolism · doi:10.1016/j.metabol.2017.09.013 · Cited by 72
Pharmacogenetics in type 2 diabetes: precision medicine or discovery tool?
Florez, J. C. (2017) · Diabetologia · doi:10.1007/s00125-017-4227-1 · Cited by 71
Nagahisa, T., & Saisho, Y. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-00680-5 · Cited by 71
SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment
Scheen, A. J. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.1100167 · Cited by 70
Continual evolution of type 2 diabetes: an update on pathophysiology and emerging treatment options
Cornell, S. A. (2015) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s67387 · Cited by 70
Shestakova, M. V., & Александровна, Ю. Е. (2015) · Diabetes Mellitus · doi:10.14341/dm20151s1-112 · Cited by 70
Yang, W., Han, P., Min, K., Wang, B., Mansfield, T. A., T'joen, C., Iqbal, N., JOHNSSON, E. K., & Ptaszynska, A. (2015) · Journal of Diabetes · doi:10.1111/1753-0407.12357 · Cited by 70
Liu, J., Li, L., Deng, K., Xu, C., Busse, J. W., Vandvik, P. O., Li, S., Guyatt, G. H., & Sun, X. (2017) · BMJ · doi:10.1136/bmj.j2499 · Cited by 70
Shin, A., Koo, B. K., Lee, J. Y., & Kang, E. H. (2024) · BMJ · doi:10.1136/bmj-2024-079475 · Cited by 69
Bioactive peptides in fermented foods and their application: a critical review
Chourasia, R., Phukon, L. C., Abedin, M. M., Padhi, S., Singh, S. P., & Kumar, A. (2022) · Systems Microbiology and Biomanufacturing · doi:10.1007/s43393-022-00125-4 · Cited by 69
Standl, E., Schnell, O., McGuire, D. K., Ceriello, A., & Rydén, L. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30033-5 · Cited by 68
Calorie Restriction Mimetics: Upstream-Type Compounds for Modulating Glucose Metabolism
Shintani, H., Shintani, T., Ashida, H., & Sato, M. (2018) · Nutrients · doi:10.3390/nu10121821 · Cited by 68
Sodium–glucose cotransporter 2 inhibitors and risk of nephrolithiasis
Kristensen, K. B., Henriksen, D. P., Hallas, J., Pottegård, A., & Lund, L. C. (2021) · Diabetologia · doi:10.1007/s00125-021-05424-4 · Cited by 68
He, W., Liu, H., Hu, L., Wang, Y., Huang, L., Liang, A., Wang, X., Zhang, Q., Chen, Y., Cao, Y., et al. (2021) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-021-00851-9 · Cited by 68
In Vitro and In Vivo Antidiabetic Potential of Monoterpenoids: An Update
Kury, L. T. A., Abdoh, A., Ikbariah, K., Sadek, B. S., & Mahgoub, M. (2021) · Molecules · doi:10.3390/molecules27010182 · Cited by 68
Creatinine‐based equations for the adjustment of drug dosage in an obese population
Bouquegneau, A., Vidal‐Petiot, E., Moranne, O. P., Mariat, C., Boffa, J., Vrtovsnik, F., Scheen, A., Krzesinski, J.-M., Flamant, M., & Delanaye, P. (2015) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12817 · Cited by 68
Dawed, A. Y., Donnelly, L. A., Tavendale, R., Carr, F., Leese, G., Palmer, C. N. A., Pearson, E. R., & Zhou, K. (2016) · Diabetes Care · doi:10.2337/dc15-2464 · Cited by 68
Müller‐Wieland, D., Kellerer, M., Cypryk, K., Skripova, D., Rohwedder, K., JOHNSSON, E. K., García‐Sánchez, R., Kurlyandskaya, R., Sjöström, C. D., Jacob, S., et al. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13437 · Cited by 68
HbA1c method performance: The great success story of global standardization
English, E., & Lenters‐Westra, E. (2018) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2018.1480591 · Cited by 68
Pasternak, B., Wintzell, V., Eliasson, B., Svensson, A., Franzén, S., Guðbjörnsdóttir, S., Hveem, K., Jonasson, C., Melbye, M., Svanström, H., et al. (2020) · Diabetes Care · doi:10.2337/dc19-2088 · Cited by 70
Trelagliptin: First Global Approval
McKeage, K. (2015) · Drugs · doi:10.1007/s40265-015-0431-9 · Cited by 68
Minimizing Glycemic Fluctuations in Patients with Type 2 Diabetes: Approaches and Importance
Dandona, P. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0372 · Cited by 67
Goto, A., Goto, M., Terauchi, Y., Yamaguchi, N., & Noda, M. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.115.002875 · Cited by 67
Cardiovascular safety of anti-diabetic drugs
Kumar, R. B., Kerins, D. M., & Walther, T. (2015) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvv035 · Cited by 67
Casanova, F., Adingupu, D. D., Adams, F., Gooding, K. M., Looker, H. C., Aizawa, K., Dove, F., Elyas, S., Belch, J. J. F., Gates, P. E., et al. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0594-7 · Cited by 67
Clinical inertia in the management of type 2 diabetes mellitus: a focused literature review
Khunti, S., Davies, M. J., & Khunti, K. (2015) · The British Journal of Diabetes · doi:10.15277/bjdvd.2015.019 · Cited by 67
Rosenblit, P. D. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0412-7 · Cited by 67
Harris, S. B., Kocsis, G., Prager, R., Ridge, T., Chandarana, K., Halladin, N., & Jabbour, S. A. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12892 · Cited by 67
Lee, R., Samsudin, M., Thirumoorthy, T., Low, L. L., & Kwan, Y. H. (2019) · Singapore Medical Journal · doi:10.11622/smedj.2019042 · Cited by 67
Overview of Therapeutic Inertia in Diabetes: Prevalence, Causes, and Consequences
Karam, S., Dendy, J. A., Polu, S., & Blonde, L. (2020) · Diabetes Spectrum · doi:10.2337/ds19-0029 · Cited by 67
Marso, S. P., McGuire, D. K., Zinman, B., Poulter, N. R., Emerson, S. S., Pieber, T. R., Pratley, R. E., Haahr, P., Lange, M., Frandsen, K. B., et al. (2016) · American Heart Journal · doi:10.1016/j.ahj.2016.06.004 · Cited by 66
Self-citationThong, K. Y., YADAGIRI, M., Barnes, D., Morris, D. S., Chowdhury, T. A., Chuah, L. L., Robinson, A. M., Bain, S. C., Adamson, K., & Ryder, R. E. J. (2017) · Primary care diabetes · doi:10.1016/j.pcd.2017.06.004 · Cited by 66
Adu, M. D., Malabu, U. H., Callander, E. J., Malau‐Aduli, A. E. O., & Malau‐Aduli, B. S. (2018) · JMIR mhealth and uhealth · doi:10.2196/10115 · Cited by 66
Giorgino, F., Penfornis, A., Pechtner, V., Gentilella, R., & Corcos, A. (2018) · Patient Preference and Adherence · doi:10.2147/ppa.s151736 · Cited by 66
Ruiz, P. L., Stene, L. C., Bakken, I. J., Håberg, S. E., Birkeland, K. I., & Gulseth, H. L. (2018) · Diabetologia · doi:10.1007/s00125-018-4681-4 · Cited by 66
Standl, E., Stevens, S. R., Lokhnygina, Y., Bethel, M. A., Buse, J. B., Gustavson, S. M., Maggioni, A. P., Mentz, R. J., Hernandez, A. F., & Holman, R. R. (2020) · Diabetes Care · doi:10.2337/dc19-1079 · Cited by 65
Self-citationScheen, A. J. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.06.008 · Cited by 65
An Update on the Molecular and Cellular Basis of Pharmacotherapy in Type 2 Diabetes Mellitus
Mahgoub, M., Ali, I. I., Adeghate, J. O., Tekes, K., Kalász, H., & Adeghate, E. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119328 · Cited by 65
Ramakrishna, R., Sarkar, D., Schwarz, P. B., & Shetty, K. (2017) · Industrial Crops and Products · doi:10.1016/j.indcrop.2017.03.033 · Cited by 65
Metadata
- Authors
- Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R.
- Affiliations
- Yale New Haven Hospital (US)
- Park Nicollet Health Services (US)
- University of North Carolina at Chapel Hill (US)
- Diabetes Center/Department of Internal Medicine, VU University Medical Center, Amsterdam, the Netherlands
- University of Pisa (IT)
- Diabeteszentrum Bad Lauterberg (DE)
- University of Southern California (US)
- Second Medical Department, Aristotle University Thessaloniki, Thessaloniki, Greece
- American Cancer Society (US)
- Churchill Hospital (GB)
- Corresponding author
- Inzucchi, Silvio E.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2014-12-13
- Volume
- 38
- Issue
- 1
- Pages
- 140-149
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2160088494
- Cited by
- 3,066
- References
- 68
- Citations by year
- 2026: 52 · 2025: 84 · 2024: 96 · 2023: 135 · 2022: 138 · 2021: 142 · 2020: 202 · 2019: 313 · 2018: 482 · 2017: 545 · 2016: 540 · 2015: 325 · 2014: 7
- FWCI
- 380.40
- Type
- journal article
- Language
- en
- Open access
- green
- pure.amsterdamumc.nl
- Licence
- other-oa
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion, other-oa)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Massachusetts General Hospital
- Yale University
- Kaiser Permanente
- F. Hoffmann-La Roche
- Case Western Reserve University
- School of Medicine, Case Western Reserve University
- Intarcia Therapeutics
- National Institute for Health and Care Research
- University of Sydney
- Universiteit van Amsterdam
- University of Toronto
- Novo Nordisk
- Uniwersytet Łódzki
- European Association for the Study of Diabetes
- Université de Nantes
- Servier
- Lilly Deutschland
- University of Ioannina
- School of Medicine, University of Kansas
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, hyperglycemia management, antidiabetic drugs, patient-centered care, shared decision-making, glucose-lowering agents, cardiovascular risk reduction, smoking cessation, blood pressure control, lipid control, statins, antiplatelet therapy, lifestyle modification
- MeSH terms
- Clinical Trials as Topic, Diabetes Mellitus, Type 2, Drug Combinations, Humans, Hyperglycemia, Metformin, United States, Disease Management, Glycemic Index, Thiazolidinediones, Dipeptidyl-Peptidase IV Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
